Financials Biotest AG

Equities

Market Closed - Xetra Other stock markets 11:36:16 2024-04-26 am EDT			5-day change	1st Jan Change
28.7 ^EUR	0.00%		+0.35%	-7.42%

Apr. 19	Biotest Launches New Plasma Collection Center in Germany	MT
Mar. 28	Biotest Aktiengesellschaft Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025
Capitalization ¹	785.5	1,126	1,609	1,520	1,456	1,391	-
Enterprise Value (EV) ¹	1,135	1,525	2,035	2,047	2,038	2,052	2,054
P/E ratio	-186 x	-36 x	-24.3 x	-43 x	9.63 x	-282 x	19.1 x
Yield	0.2%	0.14%	0.1%	0.12%	0.13%	0.07%	2.16%
Capitalization / Revenue	1.87 x	2.33 x	3.12 x	2.94 x	2.13 x	2.19 x	1.95 x
EV / Revenue	2.71 x	3.15 x	3.95 x	3.97 x	2.98 x	3.23 x	2.88 x
EV / EBITDA	37.2 x	53.9 x	-127 x	107 x	11.4 x	37.4 x	13.9 x
EV / FCF	-16,766,519 x	-34,894,916 x	-	-29,327,274 x	-	-	-
FCF Yield	-0%	-0%	-	-0%	-	-	-
Price to Book	1.7 x	2.52 x	4.02 x	3.63 x	2.46 x	3.96 x	3.4 x
Nbr of stocks (in thousands)	39,571	39,571	39,571	39,571	39,571	39,571	-
Reference price ²	20.50	28.10	38.60	34.00	31.00	28.70	28.70
Announcement Date	3/30/20	3/31/21	3/24/22	3/23/23	3/28/24	-	-

¹EUR in Million²EUR

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025
Net sales ¹	419.1	484.2	515.6	516.1	684.6	635.8	712.1
EBITDA ¹	30.5	28.3	-16	19.2	179.4	54.91	147.7
EBIT ¹	-1.2	-1.3	-47.1	16.6	143.5	15.9	106.8
Operating Margin	-0.29%	-0.27%	-9.13%	3.22%	20.96%	2.5%	15%
Earnings before Tax (EBT) ¹	-1.3	-30	-62.6	-30.8	106.3	-5.677	83.75
Net income ¹	-4.7	-31.4	-63.4	-31.7	127	-4.031	59.46
Net margin	-1.12%	-6.48%	-12.3%	-6.14%	18.55%	-0.63%	8.35%
EPS ²	-0.1100	-0.7800	-1.590	-0.7900	3.220	-0.1019	1.503
Free Cash Flow	-67.7	-43.7	-	-69.8	-	-	-
FCF margin	-16.15%	-9.03%	-	-13.52%	-	-	-
FCF Conversion (EBITDA)	-	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-	-
Dividend per Share ²	0.0400	0.0400	0.0400	0.0400	0.0400	0.0200	0.6210
Announcement Date	3/30/20	3/31/21	3/24/22	3/23/23	3/28/24	-	-

¹EUR in Million²EUR

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025
Net Debt ¹	350	399	427	528	582	661	663
Net Cash position ¹	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	11.46 x	14.1 x	-26.68 x	27.47 x	3.242 x	12.04 x	4.49 x
Free Cash Flow	-67.7	-43.7	-	-69.8	-	-	-
ROE (net income / shareholders' equity)	-	-	-	-	-	-	19.2%
ROA (Net income/ Total Assets)	-	-	-	-	-	-	-
Assets ¹	-	-	-	-	-	-	-
Book Value Per Share ²	12.10	11.20	9.610	9.380	12.60	7.250	8.440
Cash Flow per Share	-	-	-	-	-	-	-
Capex	34.1	27	-	29.3	-	-	-
Capex / Sales	8.14%	5.58%	-	5.68%	-	-	-
Announcement Date	3/30/20	3/31/21	3/24/22	3/23/23	3/28/24	-	-

¹EUR in Million²EUR

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

B-

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

28.7 EUR

Average target price

37 EUR

Spread / Average Target

+28.92%

	1st Jan change	Capi.
BIOTEST AG	-7.42%	1.48B
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B